Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Change in Accured Expenses (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Change in Accured Expenses for 16 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 12.65% to $3.5 million in Q4 2025 year-over-year; TTM through Aug 2025 was -$395998.0, a 143.7% decrease, with the full-year FY2024 number at $639063.0, down 59.61% from a year prior.
  • Change in Accured Expenses was $3.5 million for Q4 2025 at Cryo Cell International, up from -$3.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.5 million in Q4 2025 to a low of -$3.5 million in Q3 2025.
  • A 5-year average of $153383.2 and a median of -$4436.5 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 708.73% in 2022, then tumbled 2862.7% in 2023.
  • Cryo Cell International's Change in Accured Expenses stood at $1.4 million in 2021, then fell by 0.29% to $1.4 million in 2022, then soared by 142.47% to $3.4 million in 2023, then dropped by 7.86% to $3.1 million in 2024, then grew by 12.65% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Change in Accured Expenses are $3.5 million (Q4 2025), -$3.5 million (Q3 2025), and $3.1 million (Q4 2024).